Actions of terazosin and its enantiomers at subtypes of α- and α2-Adrenoceptors in vitro

References

• Luther R. R. Therapeutic Review: Terazosin: a new antihypertensive agent with favorable effects on lipids. Internat. J. Clin. Pharmacol. Ther. and Toxicol. 1989; 27: 313–319
   Google Scholar
• Meretyk S., Tang R., Shapiro E., Kyncl J. J., Lepor H. α1-adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain. The Prostate 1992; 20: 159–165
   Google Scholar
• Maruyama L., Ohkura N., Yagi Y., Nagatomo T. Comparison of displacemental potencies of terazosin enantiomers for α1-adrenoceptor subtypes. Biol. Pharm. Bull. 1994; 17: 1126–1129
   Google Scholar
• Kyncl J. J., Horrom B. W., Nordeen C. W., Juberg E. M., Bush E. N. Terazosin enantiomers: Alpha adrenoceptor interaction and antihypertensive properties. Eur. J. Pharmacol. 1990; 183: 828
   Google Scholar
• Kyncl J. J. Personal communication
   Google Scholar
• Knepper S. M., Buckner S. A., Brune M. E., DeBernardis J. F., Meyer M. D., Hancock A. A. A-61603 a potent α1-adrenergic receptor agonist, selective for the α1-A receptor subtype. J. Pharmacol. Exper. Ther. 1995; 274: 97–103
   Google Scholar
• Vodenlich A., Cain J., Buckner S., Janis R., Maldonado C., Kerkman D., DeBernardis J., Okasinski G., Hancock A. A. Characterization of subtypes of human α2 adrenergic receptors expressed in mouse fibroblast cells. The FASEB J. 1993; 7: A695
   Google Scholar
• Hancock A. A., Vodenlich A. D., Maldonado C., Janis R. α2-Adrenergic agonist-induced inhibition of cyclic AMP formation in transfected cell lines using a microtiter-based scintillation proximity assay. Journal of Receptor and Signal Transduction Research 1995; 15: 557–579
   PubMed Web of Science ®Google Scholar
• Buckner S. A., Oheim K., Morse P., Knepper S., Hancock A. A., Kerwin J. F., Jr. Functional and radioligand binding evidence for an α1 D-adrenoceptor subtype mediating contraction in the rat aorta. The FASEB Journal 1995; 9: A106
   Google Scholar
• Ireland L. M., Knepper S., Buckner S. A., Brune M., Hancock A. A., Kerwin J. F., Jr. Comparison of α1 adrenergic receptor subtypes in receptor binding and functional models. The FASEB Journal 1995; 9: A105
   Google Scholar
• Kyncl J. J., Horrom B. W. R(+) Terazosin, World Patent. WO92/00073, 1992
   Google Scholar
• Bylund D. B., Eikenberg D. C., Hieble J. P., Langer S. Z., Lefkowitz R. J., Minneman K. P., Molinoff P. B., Ruffolo R. R., Jr., Trendelenburg U. IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 1994; 46: 121–136
   PubMed Web of Science ®Google Scholar
• Ford A. P.D.W., Williams T. J., Blue D. R., Clarke D. E. α1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol. Sci. 1994; 15: 167–170
   PubMed Web of Science ®Google Scholar
• Greengrass P., Bremner R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979; 55: 323–326
   PubMed Web of Science ®Google Scholar
• Hancock A. A., Buckner S. A., Giardina W. J., Brune M. E., Lee J. Y., Morse P. A., Oheim K. W., Stanisic D. S., Warner R. B., Kerkman D. J., DeBernardis J. F. Preclinical pharmacological actions of ()-(1′R*,3R*)-3-phenyl -1- [(1′,2′,3′,4′ -tetrahydro -5′,6′ -methylene - dioxy-1′-naphthalenyl) methyl] pyrrolodine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes Alpha-2-adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J. Pharmacol. Exper. Ther. 1995; 272: 1160–1169
   Google Scholar
• Hancock A. A., Marsh C. L. Distinctions between ligand binding sites for [3 H]dopamine and D-2 dopaminergic receptors characterized with [3 H]spiroperidol. Mol. Pharmacol. 1984; 26: 439–451
   PubMed Web of Science ®Google Scholar
• Aboud R., Shafii M., Docherty J. R. Investigation of the subtypes of α1 -adrenoceptor mediating contractions of rat aorta. vas deferens and spleen, Brit. J. Pharmacol. 1993; 109: 80–87
   PubMed Web of Science ®Google Scholar
• Testa R., Guarneri L., Ibba M., Strada G., Poggesi E., Taddei C., Simonazzi I., Leonardi A. Characterization of α1-adrenoceptor subtypes in prostate and prostatic urethra of rat. rabbit, dog and man, Eur. J. Pharmacol. 1993; 249: 307–315
   PubMedGoogle Scholar
• Schild H. O. pA A new scale for the measurement of drug antagonism. Brit. J. Pharmacol. 1947; 2: 189–206
   PubMed Web of Science ®Google Scholar
• Giardina W. J., Buckner S. A., Hancock A. A., Lee J. Y., Wismer C. T., DeBernardis J. F. A-75169 HCl: Pharmacological profile and ocular pharmacology studies of a new α-2 antagonist. Drug Dev. Res. 1993; 28: 56–64
   Google Scholar
• Connaughton S., Docherty J. R. Functional evidence for heterogeneity of peripheral prejunctional alpha-2 adrenoceptors. Br. J. Pharmacol. 1990; 101: 285–290
   PubMed Web of Science ®Google Scholar
• Snedecor G:W., Cochran W. G. Statistical Methods. The Iowa State University Press, Ames Iowa 1967
   Google Scholar
• Piascik M. T., Kusiak J. W., Barron K. W. α1-Adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat. Eur. J. Pharmacol. 1990; 186: 273–278
   Google Scholar
• Brune M. E., Hancock A. A. unpublished observations
   Google Scholar
• Michel A. D., Loury D. N., Whiting R. L. Identification of a single α1-adrenoceptor corresponding to the α1 A-subtype in rat submaxillary gland. Br. J. Pharmacol. 1989; 98: 883–889
   PubMed Web of Science ®Google Scholar
• Morrow A. L., Battaglia G., Norman A. B., Creese I. Identification of subtypes of [3H]-prazosin-labelled α1 receptor binding sites in rat brain. Eur. J. Pharmacol. 1985; 109: 285–287
   Google Scholar
• Bylund D. B. Heterogeneity of alpha-2 adrenergic receptors. Pharmacol. Biochem. Behav. 1985; 22: 835–843
   PubMed Web of Science ®Google Scholar
• Hieble J. P., Naselsky D. P. Determination of α2-adrenoceptor subtype selectivity in tissue homogenates and cell lines. Pharmacologist. 1993; 35: 166
   Google Scholar
• Hoffman B. B., Lefkowitz R. J. [3H]WB4101–Caution about its role as an alpha-adrenergic subtype selective radioligand. Biochem. Pharmacol. 1980; 29: 1537–1541
   Google Scholar
• Khoury A. F., Kaplan N. M. α-Blocker therapy of hypertension: an unfulfilled promise. J. Amer. Med. Assoc. 1991; 266: 394–398
   Google Scholar
• Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 1990; 3: 75–84, Suppl)
   Google Scholar
• Hoffman B. B., De Lean A., Wood C. L., Schocken D. D., Lefkowitz R. J. Alpha-adrenergic receptor subtypes: quantitative assessment by ligand binding. Life Sci. 1979; 24: 1739–1746
   PubMed Web of Science ®Google Scholar
• Hancock A. A., Buckner S. A.B. Unpublished observations
   Google Scholar
• Starke K., Trendelenburg A. U., Limberger N. Presynaptic α2-adrenoceptors: subtype determination. Pharmacol. Commun. 1995; 6: 99–108
   Google Scholar
• Starke K. Presynaptic receptors. Ann. Rev. Pharmacol. Toxicol. 1981; 21: 7–30
   PubMed Web of Science ®Google Scholar
• Ruffolo R. R. Pharmacological and therapeutic applications of α2-adrenoceptor subtypes. Ann. Rev. Pharmacol. Tox. 1993; 33: 243–279
   PubMed Web of Science ®Google Scholar
• Davey M. J. The pharmacological basis for the use of α1 - adrenoceptor antagonists in the treatment of essential hypertension. Br. J. Clin. Pharmacol. 1986; 21: 5–S
   Google Scholar
• Titmarsh S., Monk J. P. Terazosin. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension, Drugs 1987; 33: 461–477
   Google Scholar
• Kondo K., Ohashi K., Ebiwara A. Pharmacokinetics and pharmacological effects of terazosin a new alpha-blocker, Japan. J. Clin. Pharmacol. and Ther. 1982; 13: 137–138
   Google Scholar
• Kyncl J. J., Juberg E. J. Unpublished observations
   Google Scholar